Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo Dienstmann

Showing results (31-40 of 175) with videos related to

Pageof 18
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Personalizing Adjuvant Therapy for Stage II/III Colorectal CancerNadine Jackson McCleary, Al B Benson, Rodrigo Dienstmann
Recent Patents on Anti-Cancer Drug Discovery|February 8, 2011
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2Rodrigo Dienstmann, Jordi Rodon, Ben Markman, et al.
Nature Reviews. Clinical Oncology|February 13, 2013
Development of PI3K inhibitors: lessons learned from early clinical trialsJordi Rodon, Rodrigo Dienstmann, Violeta Serra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Genomic medicine frontier in human solid tumors: prospects and challengesRodrigo Dienstmann, Jordi Rodon, Jordi Barretina, et al.
The Oncologist|December 3, 2011
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsRodrigo Dienstmann, Irene Braña, Jordi Rodon, et al.
Molecular Cancer Therapeutics|April 22, 2014
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsRodrigo Dienstmann, Jordi Rodon, Violeta Serra, et al.
JCO Global Oncology|July 10, 2023
Reply to R. Freitas-Junior et alCristiano A A Resende, Rodrigo Dienstmann, Max S Mano
Molecular Oncology|December 23, 2011
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancerRodrigo Dienstmann, Sara De Dosso, Enriqueta Felip, et al.
JCO Precision Oncology|June 10, 2021
Is It Time to Implement Adjuvant Targeted Therapy in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer?Amit A Kulkarni, Abdul Rafeh Naqash, Sonam Puri, et al.
Personalized Medicine|August 21, 2023
Challenges and opportunities in building a health economic framework for personalized medicine in oncologyPedro Nazareth Aguiar, Silvio Matsas, Rodrigo Dienstmann, et al.
Pageof 18

Showing results (31-40 of 175) with videos related to

Sort By:
Pageof 18
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Personalizing Adjuvant Therapy for Stage II/III Colorectal CancerNadine Jackson McCleary, Al B Benson, Rodrigo Dienstmann
Recent Patents on Anti-Cancer Drug Discovery|February 8, 2011
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2Rodrigo Dienstmann, Jordi Rodon, Ben Markman, et al.
Nature Reviews. Clinical Oncology|February 13, 2013
Development of PI3K inhibitors: lessons learned from early clinical trialsJordi Rodon, Rodrigo Dienstmann, Violeta Serra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Genomic medicine frontier in human solid tumors: prospects and challengesRodrigo Dienstmann, Jordi Rodon, Jordi Barretina, et al.
The Oncologist|December 3, 2011
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsRodrigo Dienstmann, Irene Braña, Jordi Rodon, et al.
Molecular Cancer Therapeutics|April 22, 2014
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsRodrigo Dienstmann, Jordi Rodon, Violeta Serra, et al.
JCO Global Oncology|July 10, 2023
Reply to R. Freitas-Junior et alCristiano A A Resende, Rodrigo Dienstmann, Max S Mano
Molecular Oncology|December 23, 2011
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancerRodrigo Dienstmann, Sara De Dosso, Enriqueta Felip, et al.
JCO Precision Oncology|June 10, 2021
Is It Time to Implement Adjuvant Targeted Therapy in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer?Amit A Kulkarni, Abdul Rafeh Naqash, Sonam Puri, et al.
Personalized Medicine|August 21, 2023
Challenges and opportunities in building a health economic framework for personalized medicine in oncologyPedro Nazareth Aguiar, Silvio Matsas, Rodrigo Dienstmann, et al.
Pageof 18